Table 2.
Comparison of laboratory parameters of COVID‐19 patients
| Median (IQR) | |||||
|---|---|---|---|---|---|
| Variables | Normal range | Total (n = 174) | High TG (n = 78) | Control (n = 96) | p‐value |
| TG (mmol/L) | <1.7 | 1.6 (1.1–2.1) | 2.2 (1.8–2.7) | 1.1 (1.0–1.3) | <.001 |
| Fasting blood glucose (mmol/L) | 4.11–6.05 | 5.7 (5.1–7.1) | 6.0 (5.3–7.9) | 5.6 (5.0–6.5) | .321 |
| HbA1c (%) | 4.0–6.0 | 6.4 (5.8–7.2) | 6.5 (6.0–7.4) | 6.2 (5.8–6.6) | .069 |
| Leukocytes (×109/L) | 3.5–9.5 | 5.0 (4.1–6.1) | 5.1 (4.3–6.5) | 4.9 (3.8–5.9) | .115 |
| Lymphocytes (×109/L) | 1.1–3.2 | 0.8 (0.5–1.4) | 0.9 (0.6–1.5) | 0.8 (0.5–1.3) | .066 |
| Serum ferritin (µg/L) | 30.0–400.0 | 654.7 (348.5–1400.7) | 798.5 (391.4–2093.8) | 566.0 (291.8–1153.9) | .001 |
| CK (U/L) | <190 | 73.0 (47.0–128.0) | 77.5 (45.5–126.3) | 69.0 (48.0–136.0) | .774 |
| LDH (U/L) | 135.0–225.0 | 286.0 (234.8–425.8) | 302.0 (238.0–473.5) | 278.0 (234.0–373.0) | .042 |
| CRP (mg/L) | <1.0 | 31.0 (5.3–100.1) | 39.8 (4.6–140.8) | 27.9 (7.3–67.5) | .035 |
| IL‐1β (pg/mL) | <5.0 | 5.0 (5.0–5.0) | 5.0 (5.0–5.0) | 5.0 (5.0–5.0) | .727 |
| IL‐2 (U/mL) | 223.0–710.0 | 714.0 (440.0–714.0) | 775.5 (421.5–1267.5) | 658.0 (440.0–1140.0) | .281 |
| IL‐6 (pg/mL) | <7.0 | 15.3 (4.0–54.8) | 20.4 (4.5–101.9) | 13.0 (3.4–40.5) | .583 |
| IL‐8 (pg/mL) | <62.0 | 12.9 (6.7–29.4) | 10.8 (6.4–22.5) | 12.8 (7.3–28.6) | .056 |
| IL‐10 (pg/mL) | <9.1 | 5.0 (5.0–7.6) | 5.0 (5.0–10.3) | 5.0 (5.0–6.2) | .045 |
| TNF‐α (pg/mL) | <8.1 | 9.2 (6.1–13.7) | 9.2 (5.8–14.0) | 9.2 (6.4–13.7) | .577 |
| ESR (mm/h) | 0.0–15.0 | 34.5 (17.0–62.0) | 33.0 (20.0–58.0) | 35.0 (17.0–63.0) | .659 |
| Fbg (g/L) | 2.0–4.0 | 5.2 (4.2–6.5) | 5.2 (3.9–6.6) | 5.3 (4.3–6.5) | .899 |
Abbreviations: CK, creatine kinase; CRP, C‐reactive protein; ESR, erythrocyte sedimentation rate; Fbg, fibrinogen; HbA1c, glycosylated hemoglobin; IL, interleukin; IQR, interquartile range; LDH, lactate dehydrogenase; TG, triglycerides; TNF‐α, tumor necrosis factor‐α.